Eye (London, England), cilt.35, sa.12, ss.3302-3310, 2021 (SCI-Expanded)
Objectives This study evaluated the efficacy of intravitreal bevacizumab (IVB) monotherapy for aggressive posterior retinopathy of prematurity (APROP) and Type 1 retinopathy of prematurity (ROP), along with recurrence rates and treatment outcomes for recurrences.